Who are DU-176b tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trintellix, Fetzima, Pristiq, Celexa, Plavix, Racemic Sibutramine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/du-176b-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

DU-176b tablets — Competitive Intelligence Brief

DU-176b tablets (DU-176b tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective serotonin reuptake inhibitor (SSRI). Area: Psychiatry.

phase 2 Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

DU-176b tablets (DU-176b tablets) — Daiichi Sankyo Co., Ltd.. DU-176b tablets are a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DU-176b tablets TARGET	DU-176b tablets	Daiichi Sankyo Co., Ltd.	phase 2	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01
Fetzima	LEVOMILNACIPRAN	AbbVie	marketed	Serotonin and Norepinephrine Reuptake Inhibitor	Sodium-dependent serotonin transporter	2013-01-01
Pristiq	desvenlafaxine	Alembic Pharms Ltd	marketed	Serotonin and Norepinephrine Reuptake Inhibitor	Sodium-dependent serotonin transporter	2008-01-01
Celexa	CITALOPRAM	AbbVie	marketed	Serotonin Reuptake Inhibitor	Sodium-dependent serotonin transporter	1998-01-01
Plavix	clopidogrel	Generic (originally Sanofi/BMS)	marketed	Thienopyridine antiplatelet agent	Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter	1997-11-17
Racemic Sibutramine	SIBUTRAMINE		marketed	Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic	Sodium-dependent serotonin transporter	1997-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective serotonin reuptake inhibitor (SSRI) class)

University of Texas Southwestern Medical Center · 3 drugs in this class
Johns Hopkins University · 2 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Daiichi Sankyo Co., Ltd. · 1 drug in this class
Guangdong Provincial People's Hospital · 1 drug in this class
Janssen Research & Development, LLC · 1 drug in this class
Medical University of Vienna · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
Fundació Sant Joan de Déu · 1 drug in this class
Centre Hospitalier Universitaire Dijon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DU-176b tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/du-176b-tablets. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab